Evidence map›Paper›PMID 38349161›Full record

ArticleAntimicrobial agents and chemotherapy2024

Identification of epidermal growth factor receptor-tyrosine kinase inhibitor targeting the VP1 pocket of human rhinovirus.

Masum Miah, Andrew M Davis, Charles Hannoun, Joanna S Said, Martina Fitzek, Marian Preston, Dave Smith, Colores Uwamariya, Ambjörn Kärmander, Thomas Lundbäck and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Masum MiahDepartment of Infectious Disease, Section for Clinical Virology, Institute of Biomedicine, University of Gothenburg, Göteborg, Sweden.
Andrew M DavisDiscovery Sciences, BioPharmaceutical R&D, AstraZeneca, Mölndal, Sweden.
Charles HannounDepartment of Infectious Disease, Section for Clinical Virology, Institute of Biomedicine, University of Gothenburg, Göteborg, Sweden.
Joanna S SaidDepartment of Infectious Disease, Section for Clinical Virology, Institute of Biomedicine, University of Gothenburg, Göteborg, Sweden.ORCID 0000-0002-4082-7374
Martina FitzekHTS Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, Macclesfield, United Kingdom.
Marian PrestonHTS Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, Macclesfield, United Kingdom.
Dave SmithDiscovery Sciences, BioPharmaceutical R&D, AstraZeneca, Cambridge, United Kingdom.
Colores UwamariyaDepartment of Infectious Disease, Section for Clinical Virology, Institute of Biomedicine, University of Gothenburg, Göteborg, Sweden.
Ambjörn KärmanderDepartment of Infectious Disease, Section for Clinical Virology, Institute of Biomedicine, University of Gothenburg, Göteborg, Sweden.
Thomas LundbäckDiscovery Sciences, BioPharmaceutical R&D, AstraZeneca, Mölndal, Sweden.ORCID 0000-0002-8145-7808
Tomas BergströmDepartment of Infectious Disease, Section for Clinical Virology, Institute of Biomedicine, University of Gothenburg, Göteborg, Sweden.
Edward TrybalaDepartment of Infectious Disease, Section for Clinical Virology, Institute of Biomedicine, University of Gothenburg, Göteborg, Sweden.ORCID 0000-0003-2384-2123
University of Gothenburg · SEAstraZeneca (United Kingdom) · GBAstraZeneca (Sweden) · SE

Funding

Stiftelsen Forska Utan Djurförsök (Swedish Fund for Research Without Animal Experiments) N2021-00012, F2022-00009Vetenskapsrådet (VR) 2018-03918, 2021-06386
6 · The paper itself

Abstract

Screening a library of 1,200 preselected kinase inhibitors for anti-human rhinovirus 2 (HRV-2) activity in HeLa cells identified a class of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) as effective virus blockers. These were based on the 4-anilinoquinazoline-7-oxypiperidine scaffold, with the most potent representative AZ5385 inhibiting the virus with EC

Indexed as

RhinovirusTyrosine Kinase InhibitorsAntiviral AgentsCapsid ProteinsErbB ReceptorsHeLa CellsHumansAntiviral AgentsCapsid ProteinsErbB ReceptorsTyrosine Kinase Inhibitorsepidermal growth factor receptorescape mutanthuman rhinovirushydrophobic pocketkinase inhibitor

Identifiers

PMID38349161
PMCPMC10916396
OpenAlexW4391786590

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.